Funding for this research was provided by:
Swedish Orphan Biovitrum (SOBI) Italia
Article History
Received: 14 June 2017
Accepted: 15 July 2018
First Online: 2 August 2018
Ethics approval and consent to participate
: Not applicable
: Not applicable
: VL, IT and GT declare that they have no conflict of interest. SOBI is not financed by Bioverativ; SOBI has entered into a commercialization partnership agreement with Bioverativ which manufactures Elocta/te for both SOBI and Bioverativ.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.